Faron enrolls first patient in Phase 1b/2 BEXAR trial of bexmarilimab plus doxorubicin in metastatic soft-tissue sarcoma

• Faron Pharmaceuticals enrolled the first patient in the Phase 1b/2 BEXAR trial of bexmarilimab with doxorubicin in metastatic soft-tissue sarcoma.
• No clinical results have been presented; the study will generate safety data first, then move to a randomized efficacy readout versus doxorubicin alone.
• The program expands bexmarilimab into a first-line solid-tumor setting with limited treatment options, aiming to improve response to standard chemotherapy.
• Trial runs at six hospitals in Spain under MEDSIR sponsorship, led by Vall d’Hebron University Hospital in Barcelona.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.